← Back to patent-cliff list
Cemsidomide
Tier C — Watch / tradeCemsidomide
C4 Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IKZF3, IKZF1
Indications (approved)：Multiple myeloma, Non-Hodgkin lymphoma
Regional status
US
Phase II
2026-02-18
EU
Phase II
2026-02-18
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cemsidomide?
Approved indications include: Multiple myeloma, Non-Hodgkin lymphoma.
When does the Cemsidomide patent expire?
No public expiry year is available for Cemsidomide yet; this page updates once verified.
How do I get a quote for Cemsidomide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29